IBRX vs NXPI · rev $51.2M vs P/E 29, rev $12.27B
Immunitybio Inc (IBRX) versus NXP Semiconductors NV (NXPI) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
NXP Semiconductors NV (NXPI) is a semiconductors company listed on NASDAQ.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
Latest reported NXPI revenue for 2025-12-31 was $12.27B. Net income was $2.02B. Revenue was down 2.7% from 2024-12-31 to 2025-12-31. NXPI currently screens at market cap $76.47B and trailing P/E 29.0.
IBRX currently screens at market cap $7.88B. NXPI currently screens at market cap $76.47B and trailing P/E 29.0.
Not investment advice. Open the IBRX and NXPI stock pages for the full models.
Not investment advice.